Development of a small-molecule immunomodulator for the treatment of melanoma
Ended Project Grant Awarded Last action
- Award ID
- R41CA261311
- Recipient
-
Claradele Pharmaceuticals Inc. UEI CC1MBJJNJ7E9
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $796,484
Award facts
- Assistance listing
- 93.395 Cancer Treatment Research
- Completion date
- Originally
- Place of performance
- North Carolina, USA
Award details come from USAspending.gov.
Description
- Abstract
- Melanoma is the most lethal form of skin cancer with treatment costs exceeding $3 billion each year. Melanoma is successfully managed at early stages however, five-year survival rates for the advanced disease are as low as 20%. Immunotherapeutic checkpoint inhibitors (ICI) including agents that target PD1/PD-L1, have substantially improved melanoma survival rates. Unfortunately, only 35-60% of melanoma patients exhibit complete or partial responses to icis. Moreover, melanoma tumors that have mutations in the braf protooncogene rapidly develop resistance to braf/MEK inhibitors. Few treatment options remain for patients who fail to respond to icis or have developed resistance to braf inhibitors. To prolong the lives of these individuals, optimized ICI regimens that are effective in ICI- and braf-resistant melanoma are urgently needed. Claradele pharmacetuicals is investigating whether pretreating melanoma with the novel, small molecule immunostimulatory endoplasmic reticulum (ER) stress inducer, 15DPMJ2, will sensitize the lesions to PD1 blockade. Our data demonstrate that 15DPMJ2 inhibited subcutaneous melanoma growth. In addition, 15DPMJ2 increased the tumor infiltration of active dendritic and memory t cells. Studies in this project will define doses of 15DPMJ2 that are safe to administer with anti-PD1 by determining the optimal biological dose (OBD). We will also test whether generating tumor inflammation with intratumorally administered 15DPMJ2 increases the rate at which melanoma responds to PD1 blockade. Our syngeneic murine models will be used to examine the effects of 15DPMJ2 on melanoma that contains or is devoid of human driver braf mutations. Accomplishing our goals will provide proof-of-concept that optimizing the activity of icis with 15DPMJ2 will allow a significant proportion of melanoma patients to benefit from these life-saving therapeutics. The knowledge gained from this investigation will form the foundation of a phase II sttr application that will examine agent formulation, optimize medicinal chemistry parameters, develop a CMC package, and define key toxicology and pharmacology properties of 15DPMJ2 to support an IND submission to the FDA.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $398,242 | |
| Original award | $398,242 |
Quick answers
Who received award R41CA261311?
R41CA261311 was awarded to Claradele Pharmaceuticals Inc. by National Cancer Institute (National Institutes of Health) on July 1, 2022.
How much is award R41CA261311 worth?
$796,484 has been obligated on R41CA261311.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award